Malignant neoplasm of unspecified part of adrenal gland
ICD-10 C74.9 is a billable code used to indicate a diagnosis of malignant neoplasm of unspecified part of adrenal gland.
C74.9 refers to a malignant neoplasm located in the adrenal gland, where the specific site within the gland is not specified. The adrenal glands, located atop each kidney, are responsible for producing hormones that regulate metabolism, immune response, blood pressure, and stress responses. Malignant neoplasms in this area can disrupt normal hormone production, leading to various metabolic disorders. Common types of adrenal malignancies include adrenal cortical carcinoma and pheochromocytoma, which can lead to excess production of hormones such as cortisol and catecholamines. Symptoms may include hypertension, weight gain, and abnormal glucose metabolism. Diagnosis typically involves imaging studies, hormone level assessments, and histopathological examination following biopsy. Treatment often requires surgical intervention, chemotherapy, or radiation therapy, depending on the tumor's characteristics and stage. Accurate coding is essential for proper treatment planning and reimbursement, as well as for tracking epidemiological data related to adrenal malignancies.
Detailed hormone level assessments, imaging results, and treatment plans.
Patients presenting with symptoms of hormonal imbalance, such as Cushing's syndrome or adrenal insufficiency.
Endocrinologists must ensure comprehensive documentation of hormonal assays and imaging studies to support the diagnosis.
Pathology reports, staging information, and treatment protocols.
Patients undergoing surgical resection of adrenal tumors or receiving chemotherapy.
Oncologists should document tumor characteristics and response to treatment to ensure accurate coding.
Used for surgical removal of adrenal tumors.
Operative report detailing the procedure and findings.
Endocrinologists and oncologists must ensure accurate coding based on surgical findings.
Documentation should include imaging studies, pathology reports confirming malignancy, and any relevant hormone level assessments. Clear clinical notes detailing the patient's symptoms and treatment plans are also essential.
